1-(4-nitro-2-(trifluoromethyl)phenyl)piperidin-4-amine | 1179605-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(4-nitro-2-(trifluoromethyl)phenyl)piperidin-4-amine
• 英文别名: 1-[4-Nitro-2-(trifluoromethyl)phenyl]piperidin-4-amine
• CAS: 1179605-04-9
• 化学式: C₁₂H₁₄F₃N₃O₂
• 分子量: 289.257
• InChiKey: DUFURTITKJKHIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.1
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-(4-nitro-2-(trifluoromethyl)phenyl)piperidin-4-amine 在 盐酸 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 72.0h， 生成 1-benzo[b]thiophen-3-yl-3-[1-(4-nitro-2-trifluoromethylphenyl)piperdin-4-ylamino]propan-1-one hydrochloride
  参考文献：
  名称：

  Novel Benzo[b]thiophene Derivatives as New Potential Antidepressants with Rapid Onset of Action

  摘要：

  We report benzo[b]thiophene derivatives synthesized according 10 a dual strategy. 8j, 9c, and 9e with affinity values toward 5-HT(7)R and 5-HTT were selected to probe their antidepressant activity in vivo using the forced swimming text (FST). The results slowed significant antidepressant activity after chronic treatment. 9c was effective in reducing the immobility time in FST even after acute treatment. These findings identify these compounds as a new class of antidepressants with a rapid onset of action.

  DOI：

  10.1021/jm2000773
• 作为产物：
  描述：

  2-氟-5-硝基三氟甲苯 在 盐酸 、 potassium carbonate 作用下， 以 溶剂黄146 、 乙腈 为溶剂， 反应 2.0h， 生成 1-(4-nitro-2-(trifluoromethyl)phenyl)piperidin-4-amine
  参考文献：
  名称：

  新的抗疟疾1-芳基-3-取代丙醇衍生物的结构活性关系：合成，初步毒性分析，寄生虫生命周期阶段研究，目标探索和目标交付。

  摘要：

  设计，合成，构效关系，细胞毒性研究，计算机模拟药物，遗传毒性筛选以及新的1-芳基-3-取代丙醇衍生物的体内研究导致了九种化合物的体外鉴定（55， 56、61、64、66和70-73）和体内（66和72）针对恶性疟原虫和柏氏疟原虫的抗疟药谱。化合物55、56、61、64、66和70-73对抗氯喹菌株FCR-3（IC50s <0.28μM）表现出强大的抗疟原虫活性，化合物55、56、64、70、71和72显示出强大的生物活性在对氯喹敏感和耐多药的菌株中的活性（3D7，D6，FCR-3和C235的IC50 <0.7μM）。所有这些化合物均具有适当的药物相似性和适当的选择性指数（77

  DOI：

  10.1016/j.ejmech.2018.04.038

文献信息

• 一类新型的FLT3激酶抑制剂及其用途
  申请人：合肥中科普瑞昇生物医药科技有限公司

  公开号：CN106543143B

  公开（公告）日：2019-03-22

  本发明提供了一种新型激酶抑制剂，其包括式(I)的化合物或其药学可接受的盐、溶剂化物、异构体、酯、酸、代谢物、或前药。本发明还提供包括式(I)化合物的药物组合物及其用于预防或治疗细胞增殖性病症和/或FLT3、c‑Kit相关病症的用途和方法，以及响应于FLT3激酶(尤其是FLT3/ITD突变型激酶)抑制的病症。
• Structure-activity relationship of new antimalarial 1-aryl-3-susbtituted propanol derivatives: Synthesis, preliminary toxicity profiling, parasite life cycle stage studies, target exploration, and targeted delivery
  作者：Miguel Quiliano、Adriana Pabón、Ernest Moles、Leonardo Bonilla-Ramirez、Isabelle Fabing、Kim Y. Fong、Diego A. Nieto-Aco、David W. Wright、Juan C. Pizarro、Ariane Vettorazzi、Adela López de Cerain、Eric Deharo、Xavier Fernández-Busquets、Giovanny Garavito、Ignacio Aldana、Silvia Galiano

  DOI：10.1016/j.ejmech.2018.04.038

  日期：2018.5

  Design, synthesis, structure-activity relationship, cytotoxicity studies, in silico drug-likeness, genotoxicity screening, and in vivo studies of new 1-aryl-3-substituted propanol derivatives led to the identification of nine compounds with promising in vitro (55, 56, 61, 64, 66, and 70-73) and in vivo (66 and 72) antimalarial profiles against Plasmodium falciparum and Plasmodium berghei. Compounds

  设计，合成，构效关系，细胞毒性研究，计算机模拟药物，遗传毒性筛选以及新的1-芳基-3-取代丙醇衍生物的体内研究导致了九种化合物的体外鉴定（55， 56、61、64、66和70-73）和体内（66和72）针对恶性疟原虫和柏氏疟原虫的抗疟药谱。化合物55、56、61、64、66和70-73对抗氯喹菌株FCR-3（IC50s <0.28μM）表现出强大的抗疟原虫活性，化合物55、56、64、70、71和72显示出强大的生物活性在对氯喹敏感和耐多药的菌株中的活性（3D7，D6，FCR-3和C235的IC50 <0.7μM）。所有这些化合物均具有适当的药物相似性和适当的选择性指数（77
• [EN] NOVEL FLT3 KINASE INHIBITOR AND USES THEREOF<br/>[FR] NOUVEL INHIBITEUR DE LA KINASE FLT3 ET SES UTILISATIONS<br/>[ZH] 一类新型的FLT3激酶抑制剂及其用途
  申请人：PRECEDO PHARMACEUTICALS CO LTD

  公开号：WO2017049462A1

  公开（公告）日：2017-03-30

  本发明提供了一种新型激酶抑制剂，其包括式(I)的化合物或其药学可接受的盐、溶剂化物、异构体、酯、酸、代谢物、或前药。本发明还提供包括式(I)化合物的药物组合物及其用于预防或治疗细胞增殖性病症和/或FLT3、c-Kit相关病症的用途和方法，以及响应于FLT3激酶(尤其是FLT3/ITD突变型激酶)抑制的病症。
• Novel Benzo[<i>b</i>]thiophene Derivatives as New Potential Antidepressants with Rapid Onset of Action
  作者：Luis Berrade、Bárbara Aisa、María J. Ramirez、Silvia Galiano、Salvatore Guccione、Lise Román Moltzau、Finn Olav Levy、Ferdinando Nicoletti、Giuseppe Battaglia、Gemma Molinaro、Ignacio Aldana、Antonio Monge、Silvia Perez-Silanes

  DOI：10.1021/jm2000773

  日期：2011.4.28

  We report benzo[b]thiophene derivatives synthesized according 10 a dual strategy. 8j, 9c, and 9e with affinity values toward 5-HT(7)R and 5-HTT were selected to probe their antidepressant activity in vivo using the forced swimming text (FST). The results slowed significant antidepressant activity after chronic treatment. 9c was effective in reducing the immobility time in FST even after acute treatment. These findings identify these compounds as a new class of antidepressants with a rapid onset of action.
• Alsinol, an arylamino alcohol derivative active against Plasmodium, Babesia, Trypanosoma, and Leishmania: past and new outcomes
  作者：Maria H Arias、Miguel Quiliano、Sandra Bourgeade-Delmas、Isabelle Fabing、Isabelle Chantal、David Berthier、Cécile Minet、Veronique Eparvier、Jonathan Sorres、Didier Stien、Silvia Galiano、Ignacio Aldana、Alexis Valentin、Giovanny Garavito、Eric Deharo

  DOI：10.1007/s00436-020-06832-y

  日期：2020.10

  Malaria, babesiosis, trypanosomosis, and leishmaniasis are some of the most life-threatening parasites, but the range of drugs to treat them is limited. An effective, safe, and low-cost drug with a large activity spectrum is urgently needed. For this purpose, an aryl amino alcohol derivative called Alsinol was resynthesized, screened in silico, and tested againstPlasmodium,Babesia,Trypanosoma, andLeishmania. In silico Alsinol follows the Lipinski and Ghose rules. In vitro it had schizontocidal activity againstPlasmodium falciparumand was able to inhibit gametocytogenesis; it was particularly active against late gametocytes. In malaria-infected mice, it showed a dose-dependent activity similar to chloroquine. It demonstrated a similar level of activity to reference compounds againstBabesia divergens, and against promastigotes, and amastigotes stages ofLeishmaniain vitro. It inhibited the in vitro growth of two African animal strains ofTrypanosomabut was ineffective in vivo in our experimental conditions. It showed moderate toxicity in J774A1 and Vero cell models. The study demonstrated that Alsinol has a large spectrum of activity and is potentially affordable to produce. Nevertheless, challenges remain in the process of scaling up synthesis, creating a suitable clinical formulation, and determining the safety margin in preclinical models.